ENDRA Life Sciences Inc (OQ:NDRA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 3600 Green Ct Ste 350
ANN ARBOR MI 48105-2440
Tel: 1-310-6917100
Website: https://www.endrainc.com
IR: See website
<
Key People
Francois Roger Michelon
Chairman of the Board, Chief Executive Officer
Irina Pestrikova
Senior Director of Finance
Michael Milos Thornton
Chief Technology Officer
Business Overview
ENDRA Life Sciences Inc. develops technology for increasing the capabilities of clinical diagnostic ultrasound to broaden patient access to the diagnosis and treatment of various medical conditions in circumstances where other diagnostic technologies are unavailable or impractical. The Company has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and staging the progression of non-alcoholic fatty liver disease (NAFLD), which, if untreated, can progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The Company's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
Financial Overview
For the nine months ended 30 September 2023, ENDRA Life Sciences Inc revenues was not reported. Net loss decreased 13% to $8.6M. Lower net loss reflects Other income (expense) increase from $45K (expense) to $462K (income), Research and development decrease of 10% to $4.4M (expense), Other SGA decrease of 39% to $673K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$3.58 to -$1.76.
Employees: 21 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $3.63M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$12.24M as of Sep 30, 2023
Net annual income (TTM): -$11.89M as of Sep 30, 2023
Free cash flow (TTM): -$10.53M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 8,454,922 as of Nov 14, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.